<DOC>
	<DOCNO>NCT02014649</DOCNO>
	<brief_summary>This Phase 1/2 protocol design collect safety , tolerability pharmacokinetic data two dos Laninamivir Octanoate child adolescent . The protocol also explore virology efficacy endpoint .</brief_summary>
	<brief_title>Safety &amp; Pharmacokinetics Study Inhaled Laninamivir Octanoate TwinCaps® Dry Powder Inhaler Children With Influenza</brief_title>
	<detailed_description>Approximately 48 subject age 5-17 year inclusive randomise study . Subjects recent onset presumptive influenza influenza A B infection confirm Rapid Antigen Test . The study conduct outpatient basis . The dose administer single session clinic Day 1 . The subject return clinic assessment follow .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Zanamivir</mesh_term>
	<criteria>Subjects ' parent/legally acceptable representative/guardian must give write informed consent participate study must understand nature study must willing comply protocol requirement . Subjects 12 must provide assent participate study potential subject age provide assent deem appropriate maturity level subject require accord local guidance/regulations . Males female age 5 17 year inclusive , weigh least 15 kg screening . Confirmed influenza infection base positive rapid antigen test ( RAT ) Influenza A B . Fever , define either : 1 . Otic temperature ≥38.0° C ( 100.4°F ) screen visit , OR , 2 . A history fever within 24 hour prior screen visit administer antipyretic ( ) 6 hour prior screen visit . Presence Screening questionnaire , least two , follow influenza symptom : 1 . Nonproductive Cough , least moderate severity , 2 . Sore throat , least moderate severity , 3 . Nasal congestion/runny nose , least moderate severity , 4 . Headache , least moderate severity , 5 . Muscle ache pain , least moderate severity , 6 . Feeling feverish , least moderate severity , 7 . Low energy , tire , fatigue , least moderate severity ; Onset illness 40 hour randomization , define : 1. time temperature first measure elevate ≥38.0°C ( oral otic ) OR 2. time subject first experience least one influenza symptom ( nonproductive cough , sore throat nasal congestion/runny nose , headache , muscle ache pain , feel feverish , low energy/tired/fatigue ) In Investigator 's opinion able complete require inhalation investigational medicinal product . Use antiviral treatment influenza ( e.g. , zanamivir , oseltamivir , peramivir , rimantadine , amantadine ) within 14 day prior screen Received influenza virus vaccine previous 3 week . History presence clinically significant pulmonary disease ( e.g. , chronic obstructive pulmonary disease , cystic fibrosis , bronchiectasis ) Current asthma require treatment , history asthma require treatment last 5 year , episode wheeze 12 month prior randomization . History congestive heart failure symptom consistent New York Heart Association Class III IV functional status . Presence immune compromise status due chronic illness , organ transplantation use daily systemic immunosuppressant Presence clinically significant sign acute respiratory distress screen . Current use inhale medication ( nasal oral ) anticipate use inhaled medication ( nasal oral ) time study . Current history acute chronic renal impairment/disease Currently hospitalize plan hospitalization within 1 month follow last dose IMP . Current clinical evidence otitis , bronchitis , sinusitis , pneumonia active bacterial infection body site Severe infection within 30 day prior screen require parenteral antibiotic use hospitalization .</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Influenza treatment</keyword>
	<keyword>pediatric</keyword>
	<keyword>laninamivir</keyword>
</DOC>